Cagrilintide vs Tirzepatide

Overview

This comparison separates Cagrilintide and Tirzepatide for reference—not product selection.

Cagrilintide: Long-acting amylin analogue studied on its own and combined with semaglutide in obesity trials.

Tirzepatide: Dual GIP and GLP-1 receptor agonist, approved for type 2 diabetes and weight management.

Differences

• Cagrilintide is discussed in relation to calcitonin receptor; Tirzepatide is discussed in relation to GLP-1 receptor.
• Both appear in Metabolic & GLP-1 research literature, but mechanistic framing differs.

Mechanism

Cagrilintide: Amylin is released with insulin after eating and contributes to feeling full. Cagrilintide acts on the same receptors — the amylin and calcitonin receptors — bu…

Tirzepatide: Tirzepatide acts on two hormone pathways at once — the GIP and GLP-1 receptors. Both hormones are released by the gut after a meal and both increase insulin rel…

Pharmacology

Cagrilintide: Pharmacokinetic detail should be read from primary literature.

Tirzepatide: Pharmacokinetic detail should be read from primary literature.

Research

Cagrilintide: Metabolic & GLP-1 research: Phase 3 trials demonstrate significant weight loss.

Tirzepatide: Metabolic & GLP-1 research: Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.

Summary

Distinction

• AXIOM does not provide dosing, administration, or protocol guidance.
• Catalogue links appear only where AXIOM lists a research-use product.
• Reference-only compounds remain comparison terms without implying availability.

References

• pubmed.ncbi.nlm.nih.gov/37364590/
• pubmed.ncbi.nlm.nih.gov/40544432/
• pubmed.ncbi.nlm.nih.gov/40544433/
• pubmed.ncbi.nlm.nih.gov/41406444/
• pubmed.ncbi.nlm.nih.gov/38912654/
• pubmed.ncbi.nlm.nih.gov/37385275/
• pubmed.ncbi.nlm.nih.gov/39536238/
• pubmed.ncbi.nlm.nih.gov/35658024/

Questions